To assess the prevalence of depression among fi ve large European nations. METHODS: TNS Healthcare's European Healthcare Panel of individuals in France, Germany, Italy, UK and the Netherlands were surveyed in 2007 to assess disease burden at national level. The self-reported epidemiological data is representative of population gender and age (18-24, 25-34, 35-44, 45-54, 55-64, 65-69 yrs) strata in respective countries, ensured by sampling and intensive panel management. The survey collected information on select health conditions (incl. depression; in the past 12-months), quality of life and health care-utilization. RESULTS: In the TNS European Healthcare Panel, 8,665, 25,265, 19,887, 59,850 and 47,340 individuals completed survey in the Netherlands, Germany, Italy, France and UK respectively. Prevalence of Depression varied widely between these 5 nations, as follows: Netherlands: 9.4%, Germany: 14.6%, U.K: 14.8%, France: 17.8%, Germany: 18.8%. Within each country, burden of Depression varied by age and gender; distribution among male (18-24, 25-34, 35-44, 45-54, 55-64, 65 yrs: % pts) was: the Netherlands: 5.1%, 6.0%, 7.0%, 7.6%, 7.3%, 5.1%; Germany: 10.9%, 9.9%, 11.2%, 13.7%, 10.6%, 3.7%; Italy: 9.9%, 7.4%, 9.5%, 10.9%, 11.3%, 9.4%; France: 13.7%, 12.8%, 14.4%, 14.6%, 10.9%, 6.2%; U.K: 11.8%, 12.2%, 15.8%, 18.7%, 14.0%, 7.0%; distribution among female (18-24, 25-34, 35-44, 45-54, 55-64 The pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) is made up of 14 items that assess quality of life (QoL) aspects (Total) and a 1-item overall assessment (Overall). This post-hoc analysis determined whether patient's assessment in QoL correlated with improvement as determined by the clinical assessment (i.e. PANSS; CGI-S). METHODS: A total of 302 patients (aged 13-17) with schizophrenia participated in a 6-week, multicenter, double-blind, randomized trial. The primary measure was mean change from baseline in PANSS Total score (LOCF). Secondary measures included CGI-S and the PQ-LES-Q Total and Overall. Relationships between percentage of change from baseline in PQ-LES-Q. Total and percentage of change in PANSS and between change from baseline in PQ-LES-Q Total and change from baseline in CGI-S score were tested by Pearson correlation and trend analysis (Cochran-Mantel-Haenszel). RESULTS: Aripiprazole showed signifi cant improvements over placebo in PANSS, CGI-S, and PQ-LES-Q Overall (week 6; p 0.05; LOCF). Strong correlation was found between all measures in the overall population, including PQ-LES-Q Total versus PANSS Total score and PQ-LES-Q Overall versus CGI-S (r 0.33 and 0.29; p 0.01). Analysis by treatment arm showed strong correlation between change in PQ-LES-Q Total versus change in PANSS Total in all groups (r 0.44; p 0.011; LOCF). Correlation between change in PQ-LES-Q Overall versus change in CGI-S was signifi cant in the 10 mg/day group (r 0.33; p 0.001; LOCF), but not for the 30 mg/day and placebo groups (r 0.084). Categories of CGI-S and PANSS Total improvement correlated with change in PQ-LES-Q (p 0.001; LOCF). CONCLUSIONS: Improvements in patient-assessed QoL were signifi cantly correlated with clinician reported outcomes in the overall population and in individual treatment groups. Aripiprazole 10 mg/day and the combined treatment group demonstrated a signifi cant correlation between improvements in global QoL and global severity of illness.
PMH5 PATIENT ASSESSED QUALITY OF LIFE VERSUS CLINICIAN ASSESSMENT: A POST-HOC ANALYSIS OF A TRIAL OF ARIPIPRAZOLE IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA
Wisniewski SR 1 , Whitehead R 2 , Ali M 3 , Jin N 3 , Kim E 4 , Nyilas M 5 , Carson WH 5 , Iwamoto T 5 , Mathew S 2 , Pikalov A 2 , Jing Y J g 4 1 University of Pittsburgh, Pittsburgh, PA, USA, 2 Otsuka America Pharmaceutical, Inc, Rockville, MD, USA, 3 Otsuka Pharmaceutical Development and Commercialization, Inc, Rockville, MD, USA, 4 Bristol-Myers Squibb, Plainsboro, NJ, USA, 5 Otsuka Pharmaceutical Development and Commercialization, Inc, Princeton, NJ, USA OBJECTIVES: The pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) is made up of 14 items that assess quality of life (QoL) aspects (Total) and a 1-item overall assessment (Overall). This post-hoc analysis determined whether patient's assessment in QoL correlated with improvement as determined by the clinical assessment (i.e. PANSS; CGI-S). METHODS: A total of 302 patients (aged 13-17) with schizophrenia participated in a 6-week, multicenter, double-blind, randomized trial. The primary measure was mean change from baseline in PANSS Total score (LOCF). Secondary measures included CGI-S and the PQ-LES-Q Total and Overall. Relationships between percentage of change from baseline in PQ-LES-Q. Total and percentage of change in PANSS and between change from baseline in PQ-LES-Q Total and change from baseline in CGI-S score were tested by Pearson correlation and trend analysis (Cochran-Mantel-Haenszel). RESULTS: Aripiprazole showed signifi cant improvements over placebo in PANSS, CGI-S, and PQ-LES-Q Overall (week 6; p 0.05; LOCF). Strong correlation was found between all measures in the overall population, including PQ-LES-Q Total versus PANSS Total score and PQ-LES-Q Overall versus CGI-S (r 0.33 and 0.29; p 0.01). Analysis by treatment arm showed strong correlation between change in PQ-LES-Q Total versus change in PANSS Total in all groups (r 0.44; p 0.011; LOCF). Correlation between change in PQ-LES-Q Overall versus change in CGI-S was signifi cant in the 10 mg/day group (r 0.33; p 0.001; LOCF), but not for the 30 mg/day and placebo groups (r 0.084). Categories of CGI-S and PANSS Total improvement correlated with change in PQ-LES-Q (p 0.001; LOCF). CONCLUSIONS: Improvements in patient-assessed QoL were signifi cantly correlated with clinician reported outcomes in the overall population and in individual treatment groups. Aripiprazole 10 mg/day and the combined treatment group demonstrated a signifi cant correlation between improvements in global QoL and global severity of illness.
PMH6 A COMPARATIVE REVIEW OF SAFETY, EFFICACY AND ECONOMICS OF OFF-LABEL PRESCRIBING OF LEADING ATYPICAL ANTIPSYCHOTICS

Mittal AR
St. John's University, Jamaica, NY, USA OBJECTIVES: To examine the controversial practice of off-label prescribing of atypical antipsychotic drugs and to review research evidence pertaining to the economics of their use, safety, effi cacy and appropriateness of such prescribing. METHODS: A comprehensive review of scientifi c literature published between 2001-2009, covering all empirical studies that examined off-label prescribing of atypical antipsychotics. Quantitative and qualitative analyses of published secondary data for off-label uses of three leading atypical anti-psychotics were conducted to gain insights into prevalence of off-label use, costs, and mortality associated with their use. RESULTS: Twenty experimental and observational studies qualifi ed for inclusion. Most study participants were institutionalized elderly, Caucasian men, with Alzheimer's disease. The newer atypicals accounted for more than $11 billion in annual sales and represented 90% of the antipsychotic market in 2005. There was a fi ve-fold increase in the prescription of these drugs particularly in children in the last decade and a half. Risperidone was the most prescribed drug off-label. EPS, gait disturbances and weight gain were the most commonly cited adverse events. Elderly patients with dementia-related psychosis treated with atypical antipsychotics were found to be at an increased risk of adverse events and death. CONCLUSIONS: The research evidence available to determine the true extent and consequences of off-label prescribing of atypical antipsychotics, while scarce and confl icting, is mostly critical of their use in children and elderly with dementia. Scientifi c support documenting the effi cacy and appropriateness of these drugs for treating depression and behavioral disorders of dementia is currently inconclusive. The high cost of these drugs may arguably offset the advantages stemming from their perceived lower side-effect profi le. 
PMH7 PATIENT ASSESSED QUALITY OF LIFE VS. CLINICIAN ASSESSMENT IN A TRIAL OF ARIPIPRAZOLE IN PEDIATRIC PATIENTS WITH BIPOLAR DISORDER
PMH8 GROWTH AND DIFFUSION OF ANTIPSYCHOTIC MEDICINES FOR LABELED AND OFF-LABELED USES, 1994-2007
Alexander GC 1 , Gallagher SA 1 , Mascola A 2 , Moloney R 1 , Stafford R 2 1 University of Chicago, Chicago, IL, USA, 2 Stanford University, Stanford, CA, USA OBJECTIVES: Antipsychotic drugs are widely used and costly. Little is known about how this has varied based on clinical applications and levels of evidence. METHODS: We used the IMS Health National Disease and Therapeutic Index to describe typical and atypical antipsychotic use from 1994 through 2007. We linked this nationally representative cross-sectional data from outpatient physician practices to levels of evidence and FDA approval status from the FDA and the Drugdex drug compendium. We obtained promotional and prescription expenditures from IMS Health Integrated Promotional Services and the National Prescription Audit. RESULTS: Preliminary results suggest aggregate annual antipsychotic use increased 262% from 8 million physician visits (1994) to 21 million (2006), then declined to 19 million (2007) . The market share of typical antipsychotics decreased from 86% to 8% over this time period. Large increases in antipsychotic use occurred among individuals 18-64 (234%) and 18 years of age (559%). Increases were more modest among those 65 years of age or older (131%). Antipsychotic use for schizophrenia
